mTOR inhibitors (e.g., rapamycin) and AKT inhibitors have been proposed to restore DDR efficiency and suppress tumor growth in obesity-driven cancers [141]. The gene discussed is MTOR; the disease is obesity due to melanocortin 4 receptor deficiency.